Analysts See $-0.34 EPS for Eidos Therapeutics, Inc. (EIDX)

October 13, 2018 - By Peter Erickson

Analysts expect Eidos Therapeutics, Inc. (NASDAQ:EIDX) to report $-0.34 EPS on November, 6.After having $-1.38 EPS previously, Eidos Therapeutics, Inc.’s analysts see -75.36 % EPS growth. The stock increased 1.63% or $0.15 during the last trading session, reaching $9.35. About 48,843 shares traded. Eidos Therapeutics, Inc. (NASDAQ:EIDX) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin amyloidosis (ATTR). The company has market cap of $343.63 million. It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. It currently has negative earnings. The firm was incorporated in 2013 and is headquartered in San Francisco, California.

More recent Eidos Therapeutics, Inc. (NASDAQ:EIDX) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping …” on September 21, 2018. Also Benzinga.com published the news titled: “The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron” on September 27, 2018. Seekingalpha.com‘s news article titled: “Eidos Therapeutics presents data from Phase 1 trial of AG10 at the 22nd Annual Scientific Meeting of the HFSA” with publication date: September 17, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>